The value of inflammation-related indicators in chemotherapy efficacy and disease-free survival of triple-negative breast cancer

Related articles

1. An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2-Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial

   This article has 17 authors:

   1. Nancy Chan
   2. Cerise Tang
   3. Dhruva Biswas
   4. Jungkyu Park
   5. Ken G. Zeng
   6. Joseph Cappadona
   7. Chuwen Liu
   8. Alec McClean
   9. Jeroen Berrevoets
   10. Linus Bao
   11. Bartosz Machura
   12. Robert J. Gray
   13. Victoria Wang
   14. Jan Witowski
   15. Krzysztof J. Geras
   16. Joseph A. Sparano
   17. TAILORx Investigators

2. Quantitative assessment of tumor immune microenvironment in context of HER2 expression in MIBC

   This article has 8 authors:

   1. Wei Du
   2. Shunsuke Koga
   3. Ranjitha Pratap Nair
   4. Rashmi Tondon
   5. Paul J Zhang
   6. Raghunath Puthiyaveettil
   7. Lin Mei
   8. Priti Lal

3. A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2− Early Breast Cancer

   This article has 14 authors:

   1. Thomas Bachelot
   2. Sylvie Chabaud
   3. Jérôme Lemonnier
   4. Paul H Cottu
   5. Florence Dalenc
   6. Frederick M. Howard
   7. Lajos Pusztai
   8. Cerise Tang
   9. Dhruva Biswas
   10. Ken Zeng
   11. Jan Witowski
   12. Krzysztof J Geras
   13. Fabrice André
   14. Frédérique Madeleine Penault-Llorca